Nexium Generics: Ranbaxy’s Exclusivity Loss Is Teva’s Gain
This article was originally published in PharmAsia News
Executive Summary
Teva’s readiness for approval prompts U.S. FDA conclusion that Ranbaxy forfeited its rights to 180-day exclusivity for AstraZeneca’s proton pump inhibitor; Ranbaxy is still making its case in court, but the episode is suggestive of FDA’s increasing emphasis on application quality.